Navigation Links
Mylan Announces Settlement Agreement with Novartis Related to Femara(R) First- to-File Opportunity
Date:12/2/2008

PITTSBURGH, Dec. 2 /PRNewswire-FirstCall/ -- Mylan Inc. (NYSE: MYL) today announced that it and its subsidiary, Mylan Pharmaceuticals Inc., have entered into a settlement agreement with Novartis Pharmaceuticals Corp., Novartis Corp. and Novartis International AG related to Letrozole Tablets, the generic version of Novartis' Femara(R).

Mylan's Vice Chairman and CEO Robert J. Coury commented: "We are very pleased to have reached this agreement, which demonstrates our ability to once again bring to market high quality, affordable medications for the patients who need them the most."

Under the agreement, Mylan is provided a patent license that will enable the company to market Letrozole Tablets, 2.5 mg, prior to the expiration of U.S. Patent No. 4,978,672. Additional terms related to the settlement remain confidential, and the agreement is subject to review by the U.S. Department of Justice and the Federal Trade Commission.

Letrozole Tablets, which are used in the treatment of breast cancer, had U.S. sales of approximately $470 million for the 12 months ending Sept. 30.

Mylan was the first company to file a substantially complete Abbreviated New Drug Application (ANDA) containing a Paragraph IV certification for the product. Currently, Mylan has 113 ANDAs pending U.S. Food and Drug Administration approval, 24 of which are potential first-to-file opportunities.

This press release includes statements that constitute "forward-looking statements," including with regard to the settlement, regulatory approvals and Mylan's future business opportunities. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from t
'/>"/>

SOURCE Mylan Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Mylan Receives Final FDA Approval for the Generic Version of the Antidepressant Sarafem(R) Pulvules(R) Capsules
2. Mylan Receives Final Approval for First-to-File Generic Version of Antiepileptic Keppra(R) and Launches Immediately
3. Mylan Declares Quarterly Preferred Stock Dividend
4. Mylans Matrix First-to-File on Generic Version of Vfend(R) Antifungal
5. Mylan to Retain Dey, L.P., Its Specialty Pharmaceutical Subsidiary
6. Mylan to Offer $400 Million in Cash Convertible Notes
7. Mylan Creates New Womens Health Care Franchise; Signs Agreement with Famy Care to Develop and Supply 22 Oral Contraceptive Products
8. Mylan Reports Adjusted Diluted EPS of $0.16 for the Quarter Ended June 30, 2008
9. Mylan Declares Quarterly Preferred Stock Dividend
10. Mylan Schedules Financial Results Conference Call and Live Webcast for the Second Quarter Fiscal 2008
11. Daniel E. Crookshank Joins Mylan as Vice President - Investor Relations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/21/2014)... December 22, 2014 BellasDress.com offers a ... for women. Today, it announces its BellasDress Christmas ... at its online store. , BellasDress is a famous ... to its fans through a series of promotions. The ... every customer. , “We are proud of offering ...
(Date:12/21/2014)... New York (PRWEB) December 21, 2014 ... and other product liability claims involving a class ... mimetics continue to move forward in a federal ... Southern District of California, Bernstein Liebhard LLP reports. ... Court has established a data cut-off date of ...
(Date:12/21/2014)... AlignLife of Norton Shores is spreading Christmas joy ... helping people get their health back. Mission for area ... those persons in Muskegon County who are unable to find ... life. Dr. Michael Rykse wanted to do a Toy Drive ... he knew he found that when he heard what MAP ...
(Date:12/21/2014)... SCI explores disability in sports ... barriers for disabled athletes with Aaron Scheidies , ... condition called juvenile macular degeneration, where he loses his ... his athletic ambitions to his vision and how he ... pioneer the way for other blind and visually impaired ...
(Date:12/21/2014)... Downey, CA (PRWEB) December 21, 2014 The ... toy drive in the Santa Ana and Whittier offices. The ... help brighten the lives of patients and their families during ... to reach out to approximately 70 children between both offices. ... With the help of Target’s community service team, store managers ...
Breaking Medicine News(10 mins):Health News:BellasDress.com Announces its BellasDress Christmas Sale 2Health News:Byetta Lawsuit News: New Order Issued in Federal Incretin Mimetics Litigation, Bernstein Liebhard LLP Report 2Health News:Byetta Lawsuit News: New Order Issued in Federal Incretin Mimetics Litigation, Bernstein Liebhard LLP Report 3Health News:Byetta Lawsuit News: New Order Issued in Federal Incretin Mimetics Litigation, Bernstein Liebhard LLP Report 4Health News:AlignLife of Norton Shores Makes a Brighter Christmas for Kids in Muskegon 2Health News:Disability in Sports on SCI TV with Triathlon World Champ Aaron Scheidies 2Health News:Disability in Sports on SCI TV with Triathlon World Champ Aaron Scheidies 3
... , , , ... August 3 Zogenix, Inc. ("Zogenix"), a privately held ... today their exclusive co-promotion agreement for Sumavel DosePro (sumatriptan ... approval in July 2009 and is a first-of-its-kind needle-free ...
... , MONDAY, Aug. 3 (HealthDay News) -- Common variants of ... increased risk of pancreatic cancer, according to U.S. researchers. , ... patients and more than 4,500 people without the disease. This ... that produce the blood types A, B or AB are ...
... enough , MONDAY, Aug. 3 (HealthDay News) -- Most American ... associated with an increased incidence of risk factors for cardiovascular ... find. , Simultaneous publication of both papers in the Aug. ... lead authors of the reports said. Both used U.S. data ...
... study published in the August issue of The Journal ... is an important tool for depicting the extent of neuroblastoma ... of the disease. Neuroblastoma accounts for six to ten percent ... percent of cancer deaths in children. Accurately identifying where in ...
... , BOSTON, Aug. 3 AMICAS, Inc. (Nasdaq: ... solutions, today announced a new contract with The Hospital of Central ... Connecticut to achieve its reading, productivity, and critical results management goals. ... ) , , The Hospital of ...
... , WALTHAM, Mass., Aug. 3 ... advisory firms for pharmaceutical and healthcare issues, finds that, from ... cause a decline of more than eight percent in the ... tract symptoms in the United States, France, Germany, Italy, Spain, ...
Cached Medicine News:Health News:Zogenix and Astellas Enter Exclusive Co-Promotion Agreement in the US for Newly Approved Sumavel(TM) DosePro(TM) 2Health News:Zogenix and Astellas Enter Exclusive Co-Promotion Agreement in the US for Newly Approved Sumavel(TM) DosePro(TM) 3Health News:Zogenix and Astellas Enter Exclusive Co-Promotion Agreement in the US for Newly Approved Sumavel(TM) DosePro(TM) 4Health News:Blood Type May Boost Pancreatic Cancer Risk 2Health News:Vitamin D Deficiency Linked to Heart Risk Factors in Kids 2Health News:Vitamin D Deficiency Linked to Heart Risk Factors in Kids 3Health News:PET can help guide treatment decisions for a common pediatric cancer 2Health News:The Hospital of Central Connecticut Chooses AMICAS 2Health News:The Hospital of Central Connecticut Chooses AMICAS 3Health News:Generic Erosion of Established Agents Will Offset Growth From Uptake of Emerging Therapies in the Market for Benign Prostatic Hyperplasia and Male Lower Urinary Tract Symptoms 2Health News:Generic Erosion of Established Agents Will Offset Growth From Uptake of Emerging Therapies in the Market for Benign Prostatic Hyperplasia and Male Lower Urinary Tract Symptoms 3
(Date:12/19/2014)... , Dec. 19, 2014   Hospira, Inc. ... of injectable drugs and infusion technologies, today announced that ... Annual Healthcare Conference on Wednesday, Jan. 14, 2015, in ... scheduled to begin at 10:30 a.m. Pacific time on ... all interested parties through a live audiocast accessible via ...
(Date:12/19/2014)... and CARDIFF-BY-THE-SEA, Calif. , ... SRNE ;  Sorrento), an oncology company ... and Conkwest, Inc., a privately-held immuno-oncology company developing ... (NK) cell-line based therapy, announced today that the ... jointly develop next generation CAR-TNK™ (pronounced as "Car-Tank") ...
(Date:12/19/2014)... Calif. , Dec. 18, 2014  Sage ... new generation of equipment for the testing of ... release of the new Luminary™ Profiler, the industry,s ... light-based measurement in a cost-effective, portable unit. ... the specific needs of the cannabis industry, the ...
Breaking Medicine Technology:Sorrento and Conkwest Announce Exclusive Global Collaboration 2Sorrento and Conkwest Announce Exclusive Global Collaboration 3Sorrento and Conkwest Announce Exclusive Global Collaboration 4Sorrento and Conkwest Announce Exclusive Global Collaboration 5Sage Analytics Develops Breakthrough System for Potency Testing of Cannabis Products 2
... , WOODCLIFF LAKE, N.J., Nov. 16 Eisai Inc. ... available for use by persons trained in the administration ... intravenous sedative-hypnotic agent indicated for monitored anesthesia care (MAC) ... The U.S. Food and Drug Administration (FDA) approved LUSEDRA ...
... , LOS ANGELES, Nov. 16 Cardo Medical, ... company based in Beverly Hills, California, announced today that ... in which it successfully raised approximately $6.2 million in ... , Cardo Medical, Inc. intends to use the proceeds ...
Cached Medicine Technology:LUSEDRA(TM) (fospropofol disodium) Injection CIV for Monitored Anesthesia Care (MAC) Sedation Now Available 2LUSEDRA(TM) (fospropofol disodium) Injection CIV for Monitored Anesthesia Care (MAC) Sedation Now Available 3Cardo Medical, Inc. Announces Closing of $6.2 Million Private Placement 2Cardo Medical, Inc. Announces Closing of $6.2 Million Private Placement 3
VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients....
The inner wall of the tube is coated with spray-dried lithium, ammonium or sodium heparin. These additives are anti-coagulants, which activate anti-thrombins, thus blocking the coagulation cascade of...
VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients....
Inquire...
Medicine Products: